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hypertension, was probably the main factor responsible for the
abnormalities that they observed.
The authors showed that the patients, who had primary pulmo-
nary hypertension, worked more slowly, did less work and recov-
ered more slowly than normal subjects. Inhaling nitric oxide
reduced the patients’ pulmonary arterial pressures, but changed
none of the above abnormal measurements. This made it difficult
to claim that the pulmonary hypertension was the cause of the
abnormal measurements. The decrease of pulmonary artery pres-
sure after inhalation of nitric oxide and possible, but undemon-
strated, increase of blood flow resembled Wilson and Ferraro’s (4)
study using hydralazine. This showed that hydralazine decreased
arterial pressure and increased cardiac output during exercise in
heart failure, but did not influence exercise oxygen consumption or
peak lactate concentration or oxygen debt (4). Dilating blood
vessels, reducing intravascular pressures and increasing blood flow
did not correct the important abnormalities in either situation.
A new clue concerning pulmonary hypertension is in the report
of Driss et al. (5) of producing tiny left ventricular infarcts that did
not change left ventricular hemodynamics or size, but caused
pulmonary hypertension. Riley et al. (1) should extend their studies
into the field of neurohumoral and other signaling to improve our
understanding of primary pulmonary hypertension.
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REPLY
We thank Dr. Krohn for his thoughtful comments. The mecha-
nism for the desaturation seen in some elite athletes is likely to be
related to the high cardiac output leaving insufficient time for
equilibration of oxygen tensions between the alveolus and alveolar
capillaries. Oxyhemoglobin desaturation in response to maximal
exercise is a very unusual finding in normal adults performing
exercise near sea level (1). Cardiac output at peak exercise is low in
patients with primary pulmonary hypertension (PPH). Desatura-
tion is unlikely to be due to the same mechanism as that occurring
in elite athletes. Arterial oxyhemoglobin desaturation is not a
feature of circulatory diseases or deconditioning.
We found that nitric oxide (NO) reduced right ventricular
systolic pressure (RVSP) at rest in our patients with PPH, but
failed to alter exercise responses. Several factors may have been
responsible: 1) Nitric oxide may not have improved cardiac output,
despite causing a fall in pulmonary vascular resistance; NO may
adversely affect the positive inotropic response to beta-adrenergic
stimulation in left ventricular dysfunction (2) resulting in reduced
cardiac contractility. 2) Hemodynamic improvement present at
rest may not have been sustained during exercise; our study was
noninvasive and we could not be sure that NO improved either
RVSP or cardiac output during exercise. 3) As proposed by Dr.
Krohn, peripheral factors may have limited the benefit of any rise
in cardiac output with NO. In patients with chronic left ventricular
failure, Wilson et al. (3,4) found an increase in cardiac output with
the acute administration of hydralazine or isosorbide dinitrate
during submaximal exercise or dobutamine during maximal exer-
cise. However, none of these drugs improved total oxygen con-
sumption, oxygen uptake across the exercising leg or venous
lactate. This paradox was attributed to a failure of “nutritive” flow
to increase in the exercising muscle. Even though peripheral
oxygen extraction is high in patients with PPH (5), it is possible
that the peripheral circulation may not have been able to distribute
appropriately any additional acute increase in cardiac output caused
by NO inhalation.
We agree that the study of neurohumoral mechanisms in PPH
may prove fruitful. Endothelin is known to be elevated in patients
with PPH (6) and may be important in promoting vascular
remodeling. At present it is unclear whether abnormalities of other
vasoactive hormones also occur. However, even if neurohumoral
abnormalities occur under conditions of circulatory stress, the
matter of discerning cause and effect will remain.
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